

153. (New) A method of treating diabetes in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 150.

Remarks

Applicants gratefully acknowledge the Examiner's withdrawal of the restriction requirement as to the species of claim 89 and the indication of allowability for claims 89-139. Following entry of the above amendments to the claims, claims 89-139 and 146-153 are pending in this application.

As newly added claims 146-153 ultimately depend from allowed claim 89 and find clear support inter alia in the application as filed at page 8, lines 25-29, at page 9, line 1 and in originally filed claims 28-31 and 34-35, it is respectfully submitted that newly added claims 146-153 are in condition for allowance and early and favorable action by the Examiner to this effect is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: September 19, 2002

Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

